Post on 25-Feb-2018
transcript
PRACTICE MODEL TRANSFORMATIONS:Achieving excellence through accountability and innovation
Clinical Dashboards:Clinical Dashboards: Integrating Institutional & Pharmacy Measures for
Success
Mi h l N di Ph D MHSMichael Nnadi, Pharm.D., MHSand
Steve Pickette, Pharm.D., BCPS
PRACTICE MODEL TRANSFORMATIONS:Achieving excellence through accountability and innovation
Measurement of a Pharmacy yClinical Practice Model and Dashboard Development:
Strategy
Mi h l N di Ph D MHSMichael Nnadi, Pharm.D., MHSVP of Pharmacy Services
Novant Health
6
Forsyth 932 60,978 104,752 25,359
Licensed Adjusted Emergency IP and OPBeds Discharges Visits Surgeries
2009 Statistics
Presbyterian 531 49,434 81,939 22,452
Rowan 268 21,588 58,320 9,666
Prince William 170 28,048 68,925 8,543
Thomasville 149 10,125 33,812 3,748
Upstate Carolina 125 7,793 31,609 3,190
Matthews 114 18 488 48 812 6 191Matthews 114 18,488 48,812 6,191
Orthopaedic Hosp 156 5,129 NA 6,889
Huntersville 60 13,292 33,935 5,731
Brunswick 60 8,617 24,223 3,798
Franklin 70 5,127 19,246 2,255
Medical Park 22 5,848 NA 11,416
Objectives
• Discuss the role of strategic planning in determining pharmacy dashboard.
• Describe effective pharmacy dashboards for measuring and demonstrating the success of pharmacy departments' clinical initiatives.
• Describe ways to communicate pharmacy services usingDescribe ways to communicate pharmacy services using dashboards.
7
Questions to Consider
• How do you determine what to measure?
• Why is it important?
• What do you measure?
• How and to whom do you communicate results?
It all begins with Strategic Planning
8
Strategic Management Framework
Pharmacy Strategic Plan2011‐2015
AdvancingNovant Pharmacy Services
In the 21st CenturyIn the 21st Century
9
Pharmacy in 2015
C Ph S h S
• Product‐based pharmacy services•Minimal clinical pharmacy services
•loose coalition of localized pharmacy services Strategy
• Patient centered • Operational efficiency & standardization
• Member of triad of care rounding on nursing units
• Represented in service lines as a member of the care team and in
plans
budgets
Current Pharmacy State Future Pharmacy State
of localized pharmacy services• Pharmacists manage all drug distribution •Operational inefficiencies
Strategy member of the care team and in transitions of care
• Technicians manage technology‐driven and safe medication
distribution • Safe medication practice is the
culture
plans
budgets
2015 Pharmacist
PharmacistNurse
MD
Strategy
Patient
10
Pharmacy Mission
Novant Pharmacy exists to ensure safe, effective, and affordable medication use in our communities, one person at a time.
Pharmacy Vision
Optimal medication management across all dimensions of care, every time.
11
Novant Pharmacy Values
• Compassion– We treat customers as family members, with kindness, patience, empathy and
trespect.
• Personal Excellence– We strive to grow personally and professionally. Honesty and personal
integrity guide all we do. We approach each service opportunity with a positive, flexible attitude.
• Teamwork – We support one another and collaborate in our efforts to better serve our
customers.
• Diversity – We recognize that every person is different, each shaped by unique life
experiences; this enables us to better understand one another and our customers.
Strategic Imperatives
Physician
Quality & Safety Guiding principle in our journey to deliver the most remarkable patient Experience, in every dimension, every time
Integration &
Health InformationTechnology
CommittedCommunities
EngagedEmployees
PhysicianPartners Collaborating to reach our shared vision
Building an environment that attracts the best and the brightest to practice at the top of their license
Providing medication management expertise in transitions of care, hospital to home, provider and ambulatory clinics
Implementing user-friendly, standardized, integrated technology solutions
System FinancialHealth
Partnerships& Affiliations
Integration &Strategic Growth
Best practice. No boundaries. Smart growth.
Advancing Novant Pharmacy and our profession
Maximizing efficiencies and leveraging value propositions
12
Strategic Lever:Integration & Strategic Growth
Goal: Realize “One Novant Pharmacy” with full integration of pharmacy services and economies of scale.
Best practice. No boundaries. Smart growth.
Strategies & Tactics
•Continue effort to consolidate formulary across Novant
•Document, track, and report clinical intervention outcomes and value propositions Consolidate Pharmacy policies and procedures to facilitate standardization and best practice
•Conduct gap analysis of existing pharmacy opportunities within Novant
•Develop and implement a checklist for pharmacist training to ensure optimal patient t tioutcomes every time
•Achieve clinical pharmacist deployment in all service lines
•Expand residency training programs to include PGY2
•Initiate steps in the development of new business opportunities
•Identify sources for grants to expand pharmacy clinical services in all dimensions of care
15
Strategic Lever:System Financial Health
Goal: Optimize savings opportunities enterprise‐wide
Maximizing efficiencies and leveraging value propositions
Strategies & Tactics
•Improve 340B drug savings
•Identify and implement cost savings initiatives across the system
•Consolidate all pharmacy services and leverage system‐wide contracting and integrated clinical services to maximize savings
•Investigate pharmacy revenue that is not being captured
•Achieve optimal savings from indigent drug replacement program
ll i l S i /Q ifi li i l i i ki•Fully implement Sentri‐7/Quantifi clinical intervention tracking system
•Develop and implement standardized pricing/charging algorithm for acute care pharmacies
•Identify opportunities for clinical pharmacy services and stakeholders across the system and collaborate to realize vision for one Novant Pharmacy
16
13
The currency of leadership is attention…
In most cases, if you can’t measure it, it’s probably not important…..
Performance Measurement: Benchmarking…
• Strengths:• Allows organization to evaluate your own performance in comparison
to best practice sitesto best practice sites.
• Identifies keys areas of performance excellence
• Identifies areas in need of improvement
• Identifies potential areas for new services
• Concerns:• Must understand who your comparison organizations are
― Finding apples to apples comparisons can be difficult.
• Must understand the details of what’s contained in the data― What are defined as drugs, blood factors, contrast media, IV solutions?
• Understand how acuity adjustment is included ― Is it based on Case Mix Index (CMI) or Pharmacy Intensity Score (PIS)?
14
Balanced Scorecard Approach
• What is a Balanced Scorecard?
• This is a tool that translates an organization’s mission and strategy into a comprehensive set of performance measures that provide the framework for a strategic measurement and management system.
Measure of Success
• How would we know that we are meeting our bj ti ?objectives?
• What are we measuring?
15
Category Description Goal Jan-11 Feb-11
Strategic Indicators
Employee / Customer
Satisfaction
Excellent place to work (PRC >= 90th percentile) >=40%
Excellent place to work (Int Survey) >=80%
Will Recommend to friends (Int Survey) >=80%
Employee satisfaction w/ Pharmacy (2x/ yr) (Int Survey) >=80%
Nursing satisfaction (2x/ yr) (Int Survey) >=80%
Satisfaction with Rx Management (2x/ yr) (Int Survey) >=80%
Ph i f i (PRC S ) 80%Phys satisfaction (PRC Survey) >=80%
Performance Evaluation Completed on time 100%
Turnover Rate -RPh <8%
Turnover Rate -Technicians <=12%
Turnover Rate -Others <=20%
Documented RPh Interventions 10 per 100 PD
$$ Value of Documented R.Ph Intervention $$$
Interventions Accepted 90%
Monthly Unit Inspections Completed-on site 100%
Quality / Medication
Safety
Monthly Unit Inspections Completed-off site by Rx Qtrly 100%
Monthly Unit Inspections Completed-off site by MD Office 100%
MAK override (Medication Override) <5%
Pyxis Medication Override %-Critical Care <10%
Pyxis Medication Override %-Non-Critical Units <5%
Accuracy of order entry (Nursing Intervention Data?) >98%
Medication Errors ( # of var/100 PD) 1/100
Balanced Pharmacy Scorecard
Service and Access
Pharmacy Order Entry Turn-around time "Total" <=60 mins
Pharmacy Order Entry Turn-around time "Stat" <=30 mins
Educational Program Presented to nursing 4/month
Educational Programs Presented-Medical Staff 4/month
Newsletter 1/month
Community Health Edu Community education participation 1/ Qtr
Financial Viability
IV Waste (dollars only) $
Productivity hours
Productivity dollars
Failure to Supply $ recovery $
Contract vs Invoice Price Compare (capture) $y$$ Spent on Staff development $$
Contract Compliance (Excludes sole source drugs) > 95%
% Overtime of total salary dollars <3%
Pharmacy Drug Cost vs. Budget** (Cost /APD) <100%
Patient Days Baseline
Pharmacy Adjusted Patient Days Baseline
Pharmacy Metrics
16
What is a Pharmacy Business Report?
• Pharmacy business report is a tool used by Ph L d t i t ksome Pharmacy Leaders to communicate key
information on key Pharmacy performance activities, strategic initiatives, and medication use opportunities to targeted audiences within their organization.
Things to consider when developing a Pharmacy report
• Associate the report with the department’s d I tit ti ’ l d bj tiand Institution’s goals and objectives.
• Provide executive summary
• Include relevant information and examples.
• Organize the report in easy to follow format
• Share report with executives including nursing and physicians
• Be sure to share with your pharmacy team
17
Things to consider when developing a Pharmacy report
• Use the Pharmacy report as an educational and marketing tool to the pharmacy team seniormarketing tool to the pharmacy team, senior administration, and other healthcare teams.
• Include the improvements and projects that the Pharmacy has accomplished.
• Avoid the use of questionable information that may invite scrutiny and additional questionsinvite scrutiny and additional questions.
• Ask for feedback from Pharmacy employees and mangers when compiling the report.
Communicating Pharmacy Performance:Pharmacy Business Review
2nd Quarter 2011July 2011
Submitted byMi h l N diMichael Nnadi
18
90‐Day GoalsExecutive Summary
1. Pharmacy operational expense is below budget in 2nd quarter by $1.45Mand YTD June, $3.05M
2. Drug savings for the 2nd quarter is $1.05M and YTD June, $1.8M. Key factorscontributing to savings include:contributing to savings include:‐Clinical intervention, formulary management, & collaboration with providers, $517K‐Indigent drug recovery program, $172K‐340 B drug program, contract, and inventory management, $1.15M
3. Clinical pharmacy services accomplishments includes ongoing formulary standardization, developing order sets, therapeutic substitution, nursing, provider & students education, formulary, and related cost avoidance/ savings
d f d l h d l h3. Medication safety and quality remains the guiding principles in pharmacy transformation efforts. We continue to see downward trend in medication and patient overrides compared to previous reports
4. Average pharmacy productivity remains high at 104%. Workload has increased by 1.5%.
Results
19
20
Total Savings:
$$12,933,926
Forsyth Medical CenterPharmacy Scorecard
For the Month Ending July 31, 2011 PY QTD QTD QTD Flex Budge
QTD Variance Over (Under) Flex Budget July Flex Budget
Variance Over (Under) Flex
Budget
Percent Change -
Flex Budget
Patient RevenueInpatient 14 817 826$ 13 723 171$ 15 884 950$ (2 161 779)$ 13 723 171$ 15 884 950$ (2 161 779)$ 13 6%
Current Month
Inpatient 14,817,826$ 13,723,171$ 15,884,950$ (2,161,779)$ 13,723,171$ 15,884,950$ (2,161,779)$ -13.6% Outpatient 3,930,669$ 3,933,457$ 3,769,058$ 164,399$ 3,933,457$ 3,769,058$ 164,399$ 4.4%
Total Patient Revenue 18,748,495$ 17,656,627$ 19,654,007$ (1,997,380)$ 17,656,627$ 19,654,007$ (1,997,380)$ -10.2%
Operating Expenses Salaries & Wages 952,270$ 950,078$ 867,781$ 82,297$ 950,078$ 925,444$ 24,634$ 2.7% Medical\Surgical Supplies 130,432$ 114,157$ 119,925$ (5,768)$ 114,157$ 119,925$ (5,768)$ -4.8% Drugs 2,215,046$ 1,953,770$ 2,135,377$ (181,607)$ 1,953,770$ 2,135,377$ (181,607)$ -8.5%
-$ -$ Total Operating Expenses 3,701,034$ 3,375,209$ 3,498,051$ (122,842)$ 3,375,209$ 3,498,051$ (122,842)$ -3.5%
Key Expenses Overtime Salaries 126,772$ 142,835$ -$ 142,835$ 142,835$ -$ 142,835$ 0.0% Office Supplies 5,410$ 1,821$ 4,699$ (2,878)$ 1,821$ 4,699$ (2,878)$ -61.2% Travel and Conference 249$ 155$ 2,083$ (1,928)$ 155$ 2,083$ (1,928)$ -92.5% Mileage 163$ 61$ 313$ (251)$ 61$ 313$ (251)$ -80.4%
Dietary Expenses 76$ 245$ 262$ (17)$ 245$ 262$ (17)$ -6 5% Dietary Expenses 76$ 245$ 262$ (17)$ 245$ 262$ (17)$ -6.5%
Total Key Expenses 132,670$ 145,117$ 7,356$ 137,761$ 145,117$ 7,356$ 137,761$ 1872.7%
21
Forsyth Medical CenterPharmacy Scorecard
For the Month Ending July 31, 2011 PY QTD QTD QTD Flex Budget
QTD Variance Over (Under) Flex Budget July Flex Budget
Variance Over (Under) Flex
Budget
Percent Change -
Flex Budget
Current Month
Inpatient StatisticsFacility Admissions w/ NBs 3,630 3,509 3,509 - 3,509 3,509 - 0.0%Facility Discharges w/o NBs 3,355 3,260 3,260 - 3,260 3,260 - 0.0%Facility Patient Days w/o NBs 19,334 18,078 18,078 - 18,078 18,078 - 0.0%Pharmacy SRC 1,794 1,721 1,721 - 1,721 1,721 - 0.0%Salaries & Wages per Admission 262$ 271$ 247$ 23$ 271$ 264$ 7$ 2.7%Salaries & Wages per Discharge 284$ 291$ 266$ 25$ 291$ 284$ 8$ 2.7%S l i & W P ti t D 49$ 53$ 48$ 5$ 53$ 51$ 1$ 2 7%Salaries & Wages per Patient Day 49$ 53$ 48$ 5$ 53$ 51$ 1$ 2.7%Med/Surg Supplies per Admission 36$ 33$ 34$ (2)$ 33$ 34$ (2)$ -4.8%Med/Surg Supplies per Discharge 39$ 35$ 37$ (2)$ 35$ 37$ (2)$ -4.8%Med/Surg Supplies per Patient Day 7$ 6$ 7$ (0)$ 6$ 7$ (0)$ -4.8%Drug Cost per Admission 610$ 557$ 609$ (52)$ 557$ 609$ (52)$ -8.5%Drug Cost per Discharge 660$ 599$ 655$ (56)$ 599$ 655$ (56)$ -8.5%Drug Cost per Patient Day 115$ 108$ 118$ (10)$ 108$ 118$ (10)$ -8.5%Total Operating Exp per Admission 1,020$ 962$ 997$ (35)$ 962$ 997$ (35)$ -3.5%Total Operating Exp per Discharge 1,103$ 1,035$ 1,073$ (38)$ 1,035$ 1,073$ (38)$ -3.5%Total Operating Exp per Patient Day 191$ 187$ 193$ (7)$ 187$ 193$ (7)$ -3.5%
Adjusted Discharge StatisticsAdjusted Discharges 5,126 4,875 5,002 (127) 4,875 5,002 (127) -2.5%Pharmacy Adjusted Discharges 4,245 4,194 4,034 161 4,194 4,034 161 4.0%Pharmacy Revenue per Pharmacy AD 4,417$ 4,210$ 4,873$ (663)$ 4,210$ 4,873$ (663)$ -13.6%Salaries & Wages per Pharmacy AD 224$ 227$ 215$ 11$ 227$ 229$ (3)$ -1.3%Med/Surg Supplies per Pharmacy AD 31$ 27$ 30$ (3)$ 27$ 30$ (3)$ -8.5%D C t Ph AD 522$ 466$ 529$ (64)$ 466$ 529$ (64)$ 12 0%Drug Cost per Pharmacy AD 522$ 466$ 529$ (64)$ 466$ 529$ (64)$ -12.0%Total Operating Exp per Pharmacy AD 872$ 805$ 867$ (63)$ 805$ 867$ (63)$ -7.2%
Adjusted Patient Day StatisticsAdjusted Patient Days 29,541 27,035 27,738 (703) 27,035 27,738 (703) -2.5%Pharmacy Adjusted Patient Day 24,463 23,260 22,367 892 23,260 22,367 892 4.0%Salaries & Wages per Pharmacy APD 39$ 41$ 39$ 2$ 41$ 41$ (1)$ -1.3%Med/Surg Supplies per Pharmacy APD 5$ 5$ 5$ (0)$ 5$ 5$ (0)$ -8.5%Drug Cost per Pharmacy APD 91$ 84$ 95$ (11)$ 84$ 95$ (11)$ -12.0%Total Operating Exp per Pharmacy APD 151$ 145$ 156$ (11)$ 145$ 156$ (11)$ -7.2%
340B Drug Program Contribution to Savings June YTD
NH Facility Jan-June 2011y
FMC $1,820,238TMC $69,460
Brunswick $110,167
Presbyterian $1,980,683$3,980,549
22
Additional Cost Savings Initiatives in 2nd Qtr
2nd Quarter Corporate Initiatives
Pyxis expenses avoided $600,000Conversion of Ferrlecit to Nulecit $177,867Restoration of contract Price for Eraxis $53,915Euflexxa $182,000T t l S i $1 013 782Total Savings $1,013,782
Annualized savingsCorporate pharmacy savings initiatives
YTD June 2011
Facility Sum of soft cost saved Sum of hard cost saved
Forsyth Medical Center $ 1,790,569.00 $ 344,930.00
Cost savings from Clinical Pharmacists’ activity June YTD
Medical Park Hospital $ 360,043.00 $ 24,454.00
Presbyterian Hospital - Charlotte $ 1,415,932.00 $ 126,157.00
Presbyterian Hospital - Huntersville $ 90,542.00 $ 3,949.00
Presbyterian Hospital - Matthews $ 128,949.00 $ 4,274.00
Presbyterian Orthopaedic Hospital $ 39,088.00 $ 105.00
Thomasville Medical Center $ 106,230.00 $ 11,924.00
Brunswick Community Hospital $ 4,814.00 $ 1,437.00
Grand Total $ 3,936,167.00 $ 517,230.00
23
Cost Savings per Hospital
Jan ‐ Jun 2011
$2,000,000
Cost Savings from Pharmacists’ Clinical Initiatives FY 2011
$800,000
$1,000,000
$1,200,000
$1,400,000
$1,600,000
$1,800,000
Sum of softcostsaved
Sum of hardcostsaved
$0
$200,000
$400,000
$600,000
Forsyth Medical
Center
Medical Park
Hospital
Presbyterian
Hospital ‐
Charlotte
Presbyterian
Hospital ‐
Huntersvil le
Presbyterian
Hospital ‐
Matthews
Presbyterian
Orthopaedic
Hospital
Thomasvi lle
Medical Center
Brunswick
Community
Hospital
Number of Interventions per Intervention Class
Jan ‐ Jun 2011
20646
20,000
25,000
11408
4212 4194
2171922 915 442 442 337 292 183 181 128 20
5,000
10,000
15,000
Total
442 442 337 292 183 181 128 200
Pharmacokinetics
Therapeutic
Anticoagulation NU
LL
Drug Information
Antibiotic Stewardship
Targeted Drug Program
Renal Dosing
Medication Events
IV to PO
Education/Training
Allergy Conflict Resolved
Investigational Drugs
*Not specified
(blank)
24
QUALITY IMPROVEMENTMedication Safety Event Reporting
• Pharmacy is engaged in several improvement projects including medication error reduction: MAC patient overrides
QUALITY IMPROVEMENTMedication Safety Event Reporting
Patient OverridesAll Facilities By Month
January, 2009 - June, 2011
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
8.00%
9.00%
10.00% FMC
MPH
TMC
PHC
PHM
POH
PHH
BCH
KMC
0.00%
1.00%
Janu
ary
Febr
uary
March
April
May
June
July
Augus
t
Septembe
r
Octob
er
Novem
ber
Decem
ber
Janu
ary
Febr
uary
March
April
May
June
July
Augus
t
Septembe
r
Octob
er
Novem
ber
Decem
ber
Janu
ary
Febr
uary
March
April
May
June
Override data is higher for October, 2010 due to MAC system outage on 10/21/10 and 10/22/10 and use of the recovery process.
• Pharmacy is engaged in several improvement projects including medication error reduction: MAC patient overrides
25
Operational Performance
Medication Turn Around Time: 2nd Quarter 2011 (average)
Goal BCH FMC MPH TMC KMC PHC PHH PHM POH RRMC
Routine
<=45 mins 27.47 56 20.27 51.89 33.51 28.1 16.6 35.56 30.83 4.7
Stat<=15 mins 17.76 14.47 13.37 18.3 12.86 6.93 10.43 20.66 18.76 3.13
• Pharmacy service access: Turn Around Time (TAT)
90-Day GoalsPharmacy productivity remains high for the second Quarter of 2011
Dept # FacilityHour Productivity (Includes
Orientation and Education)48706 BCH Pharmacy 95.50%
4706 FMC Pharmacy 109 60%4706 FMC Pharmacy 109.60%
6706 MPH Pharmacy 122.60%
3706 PHC Pharmacy 95.40%
2706 PHH Pharmacy 97.90%
5706 PHM Pharmacy 94.40%
9706 POH Pharmacy 84.80%
109706 PWH Pharmacy 107.90%
66706 RRMC Pharmacy 112.10%
8706 TMC Pharmacy 108.80%
118706 KMC Pharmacy 127.90%
113706 Franklin 83.7%
114706 Upstate 115.2%
Total 104.38 %
26
90-Day GoalsPharmacy Workload Continues to increase
Productivity: Orders Processed YTD
NH FacilityPrior Year
YTDCurrent
Year YTD Var (%) Variance
BCH 87,058 87,911 0.98% 853
Franklin N/A 62,423
FMC 1,096,039 1,124,607 2.61% 28,568
MPH 84,113 88,333 5.02% 4,220
TMC 84,668 98,006 15.75% 13,338
KMC N/A 23,930 100%
PHH 184,345 177,345 -3.80% -7,000
PHC 1,023,644 974,399 -4.81% -49,245
PHM 248,684 251,649 1.19% 2,965PHM 248,684 251,649 1.19% 2,965
POH 109,970 103,783 -5.63% -6,187
PWH 245,500 252,900 3.01% 7,400
RRMC 298,338 332,466 11.44% 34,128
Upstate N/A 137,543
Total: 3,462,359 3,515,329 1.53%
Lessons Learned
There is always opportunity for Therapeutic Intervention because all patients receive medications
Hospital Pharmacy is a continuously evolving practice with anHospital Pharmacy is a continuously evolving practice with an increasing emphasis on direct patient care.
Yet hospital pharmacy departments are often perceived as a “pharmaceutical materials management department” with our clinical focus being a secondary function.
Pharmacy Leaders must define and demonstrate the broad values that we deliver to our patients and institutions throughthat we deliver to our patients and institutions through measurement
27
Lessons Learned
Demonstrate your ability to create a strategic direction for your department with a clear vision of the journey
Communicate your vision for Pharmacy Practice to your teamCommunicate your vision for Pharmacy Practice to your team, nursing, physicians, and administration
Demonstrate your ability to “understand your business better than anyone else" and how it performs in comparison to others
Market your department and profession to all who will listen
PRACTICE MODEL TRANSFORMATIONS:Achieving excellence through accountability and innovation
Breakout Small Group Discussions #1
‐ Approx. 20 minutes
‐ Share examples of strategic plans
‐ Identify common key elements
‐ Lessons learned
‐ Prepare summary to present
28
PRACTICE MODEL TRANSFORMATIONS:Achieving excellence through accountability and innovation
Measurement of a Pharmacy Measurement of a Pharmacy Clinical Practice Model and
Dashboard Development
Clinical Practice Model and
Dashboard Development
Steve Pickette, Pharm.D., BCPS
Director System, Pharmacy Clinical Services
Steve Pickette, Pharm.D., BCPS
Director System, Pharmacy Clinical Services
29
Overview
Why we need Clinical Metrics and Dashboards
Examples of Dashboards:
– Clinical Service Intervention
– Hospital Interventions
– Regional Interventions
– Financial Impact– Financial Impact
– Clinical Outcomes
Conclusions
Role of the Pharmacist in Hospitals
• Reviewing individual patients’ medication orders for safety d ff ti d t ki ti ti i di t dand effectiveness and taking corrective action as indicated
• Collaboratively managing medication therapy for individual patients.
• Educating patients and caregivers about medications and their use.
• Leading continuous improvements in the medication use processprocess.
• Leading the interdisciplinary and collaborative development of mediation use policies and procedures.
30
How Common Are these Services?
2007 ASHP Survey:
Only 38% of hospitals overall have service specific pharmacists review therapy.
– 72% at hospitals greater than 400 beds
– 26% at hospitals 200 beds or less
Only 24% of hospitals have pharmacists reviewing medication therapy for 75% or morereviewing medication therapy for 75% or more of patients.
*2010 Survey: pharmacist redeployed to units in last 3 yrs 23.5%
Am J Health‐Syst Pharm—Vol 64 Mar 1, 2007 Am J Health‐Syst Pharm—Vol 67 Apr 1, 2010
Clinical Involvement
Patient
Why Are Pharmacy Clinical Service So Variable?
ProcurementAnd Storage(Turns, Line Items)
Drug Distribution(Doses Billed, TAT)
Order Processing(Orders Processed, TAT)
(No Standard Metric)
31
Pharmacy Resource Council Strategic Plan Framework
PH&S Mission, Vision & Values
We will succeed as “One Ministry Committed to Excellence”
Foundation
System Strategy
PRC Vision:Enhancing quality of life through safe & effective medication use
PRC Outcomes:• Utilize a standardized system to demonstrate the value of clinical pharmacy• 100% of CMS clinical quality indicators met relative to pharmaceutical care• Implement technology solutions to eliminate preventable medication adverse events• Pharmacist will review the therapy of 100% of patients with complex & high-risk medication
regimens • Achieve system-wide target of 90% compliance with market share contracts• Develop & adopt a standardized training and competency assessment program at least
biannually with 100% compliance• Compliance with regulatory requirements
PRC Strategic Priorities:Attract and retain the best workforce
Leverage System Wide Capabilities
Tactics: (specific Steps to Achieve Individual Strategies)
Leverage Technology
Enhance Quality & Scope of Pharmacy Clinical Services
Operating Commitments
PeopleCentered
Mission Inspired
Service Oriented
QualityFocused
FinanciallyResponsible
(specific Steps to Achieve Individual Strategies)
• Participate in and develop education programs.
• Develop HR strategy
• Career advancement
• Implement proven technology applications
• Coordinate and enhance pharmacy informatics resource
• Standardize technology
• System wide reporting tool
• Benchmark internally and externally
• Implement standard practice model
• Direct patient care
• Communicate success
• Develop Common Metrics / Benchmarking Program
• Regional P&T Process
• Shared services / resources
• Identify and share best practice
Steps In the Process
Develop Shared Need/Common Vision
D fi Obj tiDefine Objective
Develop Metrics
Initiate Pilot
Estimate ROI (Resources / Return)
Implement andMeasureImplement and Measure
Spread and Adopt
Build Upon Success
32
Shared Need / Common Vision
di ib i d d lDrug‐distribution‐centered model– Engaged with medication delivery. – Clinical role reactive to order processing.
Clinical‐pharmacist‐centered model– Engaged with medical team, but not medication use and delivery process.
P ti t t d i t t d d lPatient‐centered integrated model– Engaged with medical team and complete medication use process.
Woods, M. Practice Model Challenge. Am J Health‐Syst Pharm. 2009; 66.
PH&S “Standard” Practice ModelPH&S “Standard” Practice Model
Unit or Service‐based Clinical Staff
Defined (Specialized) Clinical Services (as much as possible)
Systematic review of medication therapy (e.g. profile review)
Prospective Involvement in Medication Therapy Decision– Rounding
– Collaborative Practice AgreementsCollaborative Practice Agreements
Efficient and Effective Distribution– Maximize Technician Resource/automation
– Centralized Order Entry
Maximize Involvement in Education – Pharmacy practice (interns, clerkships, residents)
– Other patient care team members
Documentation– Internal to pharmacyp y
– In medical record
Clinical Decision Support
Standards of Care / Protocols
Competency Standards (e.g. credentialing, training)
Professionalism (e.g. society involvement, scholarly work, etc.)
33
Initial Pilot
• Providence Sacred Heart Medical Center
• 623 bed tertiary care center
• Implementation of clinical documentation program.
• Performance Report• Trend interventions
h l• Pharmacy supply expense
• Benchmark data
Intervention Definition and ValueLEGEND: Primary Interventions – Teal Secondary Interventions – Gold Undefined - Purple
Intervention Type Primary – Teal Secondary - Gold
Intervention Class
Soft Costs Saved
Hard Costs Saved
RVU 1° 2° Quick Time Taken Description Notes/Example
*Not specified *Not specified 0 0 0 Y Y N 0 Default when no intervention type is selected. No values are applied
Prevention of an ADE that would likely have been i d d ti t MORBIDITY Ch
ADE Prevention Minor Safety 220 0 20 N Y N 20
serious and caused patient MORBIDITY. Changes in therapy occurred as a result of clinical skills and not just a computer notice (i.e. duplicate therapy, a llergy, or drug interaction notice). Must document enough information to be able to verify upon audit/review.
Example: Elderly patient sedation changed from Ambien to reduce risk of falls.
ADE Prevention Major Safety 2200 0 30 N Y N 20
Prevention of an ADE that would likely have been serious and could have resulted in MORTALITY. Changes in therapy occurred as a result of clinical skills and not just a computer notice (i.e. duplicate therapy, allergy, or drug interaction notice). Must document enough information to be able to verify upon audit/review. Use ADE Prevention Major when a history of anaphylaxis with medication ordered changed to a safer alternative.
Examples: A Category X medication is ordered for a pregnant patient (this kind of warning does not appear during order entry). Heparin is ordered for a patient with an active GI b leed.
Allergy Review Safety 0 0 15 Y N N 15 Use for identifying a llergy issues needing fo llow-up
Allergy Avoided Safety 220 0 20 N Y N 20
Use this intervention only if a therapy change was made by pharmacy to avoid an allergy. Use ADE Prevention Major when a history of anaphylaxis with medication ordered changed to a safer a lternative.
Allergy Clarified Safety 110 0 20 N Y N 20 Use this to specify types of reaction to a drug/food allergy or to clarify if patient has allergies.
Patient has allergy to penicillin. RPh verifies with patient that penicillin causes shortness of breath and hives.
34
Example: Service Line Pharmacy Savings Report
E x p e n s e s & C o s t S a v in g In it ia tiv e s p e r P h a rm a c y S e rv ic e L in e
S U R G IC A L S E R V IC E S 2 W e e k P e r io d S ta rt in g 7 /2 5 /2 0 0 4 Y e a r T o D a teS ta rt in g 6 /1 3 /0 4
E X P E N S E SS a la ry E x p e n s e 4 ,0 0 8 .0 0$ 1 5 ,0 7 8 .4 0$
C O S T S A V IN G IN IT IA T IV E S # o f In te rv e n tio n s 2 w k to ta l Y e a r T o D a teC h a n g e s M a d e in T h e ra p y
A lle rg y A v o id e d 2 1 8 2 .1 6$ 1 8 2 .1 6$ M e d O rd e r C la r if ic a tio n 3 1 2 ,8 2 3 .4 8$ 5 ,2 8 2 .6 4$ C o n s u lt 7 -$ M e d D C 'D b y R P h 1 5 1 ,3 6 6 .2 0$ 2 ,9 1 4 .5 6$ D o s e A d ju s te d 2 1 1 ,9 1 2 .6 8$ 4 ,4 6 2 .9 2$ D u p lic a te D C 'D 1 9 1 .0 8$ 2 7 3 .2 4$ D V T P ro p h y la x is b y R P h 0 -$ -$ E p o g e n U s e A v o id e d 0 -$ F o rm u la ry S u b 6 3 2 4 .0 0$ 5 9 4 .0 0$ In te ra c tio n A v o id e d 0 -$ 9 1 .0 8$ M e d C h a n g e d 0 -$ 1 8 2 .1 6$ A d ju s t fo r R e n a l F x 8 7 2 8 .6 4$ 1 ,9 1 2 .6 8$ R o u te C h a n g e d 1 6 5 6 0 .9 6$ 1 ,1 2 1 .9 2$ g $ ,$M e d S ta r te d 1 5 1 ,3 6 6 .2 0$ 2 ,3 6 8 .0 8$
O th e r In it ia t iv e sN /V -$ R o u tin e O rd e r ( ite m c o s t) -$ M is c C o s t S a v in g s -$
T O T A L C O S T S A V IN G S 9 ,3 5 5 .4 0$ 1 9 ,3 8 5 .4 4$
N E T S A V IN G S /L O S S 5 ,3 4 7 .4 0$ 4 ,3 0 7 .0 4$
Initial Service Financial Report
Expenses & Cost Saving Initiatives All Pharmacy Service Lines
2 weeks starting YTD2 weeks starting YTD7/25/2004 Starting 6/13/04Salary Expense Dollars Saved Profit/Loss Salary Expense Dollars Saved Profit/Loss
ED/OR 3,235$ 2,509$ ($726) 12,352$ 10,489$ ($1,863)ICU 6,165$ 5,340$ ($825) 21,814$ 24,092$ $2,278Peds 3,598$ 9,202$ $5,604 29,992$ 22,280$ ($7,712)NICU 3,598$ 4,977$ $1,379 10,456$ 9,928$ ($527)Peds Onc 3,923$ 8,065$ $4,141 13,366$ 18,736$ $5,370Surg 4,008$ 9,355$ $5,347 15,078$ 19,385$ $4,307Neur/Nephro 4,884$ 2,799$ ($2,085) 15,645$ 11,016$ ($4,629)Cardiology 4,070$ 7,075$ $3,005 14,815$ 12,988$ ($1,827)gy ,$ ,$ $ , ,$ ,$ ($ , )Oncology 4,070$ 5,042$ $972 14,815$ 11,509$ ($3,306)CTT 4,070$ 9,480$ $5,410 15,954$ 14,006$ ($1,949)Psych 3,253$ 2,256$ ($997) 12,044$ 5,953$ ($6,091)IMR 1,712$ 783$ ($929) 6,847$ 783$ ($6,064)
Total 46,586$ 66,883$ 20,297$ 183,178$ 161,165$ ($22,013)
35
Report from 12/12/2004
Expenses & Cost Saving Initiatives All Pharmacy Service Lines
2 weeks starting YTD2 weeks starting YTD12/12/2004 Starting 6/13/04Salary Expense Cost Saving Iniatives NET SAVINGS/LOSS Salary Expense Cost Saving Iniatives NET SAVINGS/LOSS
ED/OR 2,931$ 5,927$ $2,996 44,587$ 55,353$ $10,766ICU 4,885$ 6,410$ $1,525 78,654$ 150,632$ $71,978Peds 2,687$ 14,406$ $11,719 49,459$ 138,032$ $88,573NICU 1,647$ 3,481$ $1,834 47,117$ 55,364$ $8,247Peds Onc 3,354$ 7,926$ $4,572 53,708$ 107,795$ $54,087Surg 4,264$ 12,155$ $7,891 64,257$ 116,590$ $52,333Neur/Nephro 4,393$ 6,783$ $2,390 65,220$ 65,481$ $261C di l 3 903$ 7 419$ $3 516 59 742$ 68 275$ $8 533Cardiology 3,903$ 7,419$ $3,516 59,742$ 68,275$ $8,533Oncology 3,903$ 4,873$ $970 59,742$ 78,035$ $18,293CTT 3,908$ 16,319$ $12,411 62,312$ 99,278$ $36,966Psych 2,606$ 2,476$ ($130) 43,936$ 32,741$ ($11,195)IMR 1,224$ 308$ ($916) 23,474$ 27,494$ $4,020
Total 39,705$ 88,483$ $48,778 649,946$ 995,070$ $345,124
Cost Savings Documented Increased
Overall Pharmacy Clinical Service Profit/Loss
120000
20000
40000
60000
80000
100000
Dolla
rs
Conversion date
0
7/11
/2004
7/18
/2004
7/25
/2004
8/1/
2004
8/8/
2004
8/15
/2004
8/22
/2004
8/29
/2004
9/5/
2004
9/12
/2004
9/19
/2004
9/26
/2004
10/3/
2004
10/10
/200
4
10/17
/200
4
10/24
/200
4
10/31
/200
4
11/7/
2004
11/14
/200
4
11/21
/200
4
11/28
/200
4
2 Week Starting Date
Salary Expense Dollars Saved via Interventions/Projects
36
Drug Expense vs. Budget Improved
Drugs and Biotech Budget vs. Purchased
600000
800000
1000000
1200000
1400000
Dol
lars
PPI
0
200000
400000
Jan-03
Feb-03
Mar-03
Apr-03
May-03
Jun-03
Jul-03
Aug-03
Sep-03
Oct-03
Nov-03
Dec-03
Jan-04
Feb-04
Mar-04
Apr-04
May-04
Jun-04
Jul-04
Aug-04
Sep-04
Oct-04
Nov-04
Dec-04
Jan-05
Feb-05
Mar-05
Apr-05
May-05
Jun-05
Jul-05
Aug-05
Sep-05
Drug & Biotech Purchased Drug & Biotech Budget Linear (Drug & Biotech Purchased)
Result: Support from Administration
“The value of our model is clear both from a knowledge transfer standpoint which improves quality and also for expense controls”
Mike Wilson, President, SHMC
37
Next Step: Duplicate Results(Implement and Measure)
HFH: converted from “target drug” modelHFH: converted from target drug model
– Added 3.2 total additional F.T.E.
– Established 3 clinical services (200 beds)
SPH: “unit based order entry” model
– Centralized order review – Pyxis Connect®
– Implemented operational efficiencies– Implemented operational efficiencies• Phone tree, tech check tech, triage RPh, etc.
Documentation using clinical intervention software
Comparison of Documented Changes in Therarpy by Pharmacist 9-06 vs 9-07
800
900
1000
Warfarin Education Done
Warfarin Dosed by Pharmacist
TPN Change
Tikosyn Processed
Therapeutic duplication avoided
Sentri 7 Initiated Intervention
Sedation Protocol Change
Renal Dose Change
Count of Intervention
InterventionResults: Documentation Increased
200
300
400
500
600
700
Num
ber o
f int
erve
ntio
ns
POM Processed
PK evaluation-Vancomycin
PK evaluation-Other
PK evaluation-AG
Pain Consult or Service Change in Tx
Pain Consult Change in Tx
Non-form Changed
Lab Value Review/Change in Tx
IV-to-PO Change
IV to PO Change
IV Drug compatibility Done
Insulin Protocol Change
Indication Clarified Leading to Change
0
100
09/05 09/06 09/07 09/05 09/06 09/07
Holy Family St Patrick
Hospital/Month/Year
Education - Patient Completed
Education - Group
Duration of Therapy Changed
Drug Tx Consultation Completed
Drug Interaction Avoided
Drug Information
Dose Per Pharmacist Completed
Dose Changed AdultHospital Month/Year
38
Results: Cost Avoidance Increased
Dollars Saved
11.27
19.11
26.36
9.19
23.17
28.59
5
10
15
20
25
30
Prior to practicemodelPeriod followingpractice model
Dollars Saved Per Pt. Day
0
5
HFH HFH HFH SPH SPH SPH
Hospital / Year
9/05 9/059/06 9/069/07 9/07
Drug Expense Per Adjusted Patient Day
$60 00
$70.00
$80.00
$90.00
$10.00
$20.00
$30.00
$40.00
$50.00
$60.00
SPH $1.9 M
PHFH $2.6 M
$0.00
2005 2006 2007 2008 2009
Saint Patrick Hospital Providence Holy Family Hospital
SPH 5% Inflation HFH 5% Inflation
39
Pharmacy Supply and Labor Expense Trend Compared to Peer Hospitals
Result: More Endorsements
“I fully support the implementation of the pharmacy clinical practice model as it delivers a significant return on investment both financially and on improving quality of care”
Tom Corley, President, HFH
40
Next Step: Spread and Adopt
Approval for system wide initiative.
– Business Case
– Software Purchase
– System, Region, Service Area, Site Support
– Staffing resources• Regional Director Pharmacy Clinical Services
I l t Ph D t ti dImplement Pharmacy Documentation and Clinical Decision Support Tool
Develop Metrics to Benchmark Clinical Services
Metric Development
Core data sourcesCore data sources
– Census
– CMI
– Clinical FTE (from evaluation sheets)
– Intervention Data
• Gross intervention savings documented
41
Region HospitalLicensed
beds
Average Daily
Census Q1 2009
CMAA Daily
Average 2008
Total Staff RPh
F.T.E.
Occupied Beds Per
F.T.E.
CMAA Daily
Average Per Staff
R.Ph. F.T.E.
*Clinical F.T.E. 2006
*Clinical F.T.E. 2009
Clinical F.T.E. / 100
CMAA Daily Average 2008
Occupied Beds Per Clinical
F.T.E.
CMAA Daily Average Per
Clinical F.T.E.
WA/MT PSHMC 623 452 181 26.03 17.4 7.0 12 12 6.6 37.7 15
PSPH 390 255 107 19.8 12.9 5.4 0 6.2 5.8 41.1 17
PRMCE 372 292 151 25 11.7 6.0 0 5.3 3.5 55.1 28
PHFH 272 110 66 10.99 10.0 6.0 1 3.4 5.2 32.4 19
SPH 231 109 78 16.6 6.6 4.7 2.4 4.5 5.8 24.2 17
OR PSVMC 523 386 206 35 11.0 5.9 9.6 9.6 4.7 40.2 21
PPMC 483 287 158 27.45 10.5 5.8 1.6 7.4 4.7 38.8 21
PSJMC 360 263 94 21 12.5 4.5 0 2.4 2.6 109.6 39
LCOMT 315 104 97 11.6 10.0 8.4 2 4.8 4.9 21.7 20
CA Tarzana 245 175 15 9 19.4 1.7 1 1 6.7 175.0 15
LCOM SP 231 105 32 4.7 22.3 6.8 0 0.7 2.2 150.0 46
PHCH 206 193 72 13 14.8 5.5 0 2 2.8 96.5 36
AK PAMC 364 248 106 28 8.9 3.8 7.95 7.95 7.5 31.2 13
1363 248.17 5.5 37.55 67.25 20
MM
OO
3000
3500
4000
4500
AA
BB
CCDD
FF
HH
II
KK
LL
NN
EE
JJ
1000
1500
2000
2500
3000
$ Sa
ved
per C
MA
GG
0
500
0 10 20 30 40 50
CMAA per Clin FTE
42
Statistical Correlation
No Statistical Correlation
43
Pharmacy Clinical Intervention Metrics
“High Impact” interventions:Adverse drug event prevented allergy avoided medication dosed byAdverse drug event prevented, allergy avoided, medication dosed by pharmacy, pain consult, pharmacokinetic consult, antibiotic change, chemo dose change, TPN changed, renal dose adjustment, stress ulcer prophylaxis added, warfarin dose adjustment. Target: 15‐20 per 100 CMAA
Cost avoidance:
Estimated cost‐avoidance associated with the documented medication interventions by pharmacy. The values are provided by Solicient based on hard and soft dollar savings results in the literature evaluating the impact of the interventions. Target: $30 ‐ $75 per CMAA
Pharmacy ClinicalPharmacy Clinical Documentation Report
First thru Fourth Quarter 2010
Steve Pickette, Pharm D, BCPSDirector System Pharmacy Clinical Services
44
PHRMH
PMMC
PMH
PNMC
PPMC
PSVMC
PSH
PWFM
C
Current Outcome (through 1st Qtr)
Clinical Pharmacy Model Implementation
Implementation of clinical pharmacy practice model to minimize the risks, decrease the
costs, and improve the outcomes associated with drug therapy at 5 PHSOR facilities
a Centralized order entry
Clinical Pharmacy Practice Model Initiative
Oregon
a. Centralized order entry
b. Pharmacist in clinical units/areas
c. Systematic medication therapy review, i.e. dosing, affordability, patient education
Milestones
1Q2011
Complete gap analysis for all 8 ministries
2Q2011
Establish baselines for clinical intervention metrics
Develop action plans for implementation
Evaluate progress based on intervention metrics (see graphs and interventions tab)
3Q2011
Implement action plans
Meeting metrics for high impact interventions ? (see graphs and interventions tab)
4Q2011
Report process and outcome measures
Meeting metrics for high impact interventions ?
Report year end results
45
46
$25.00
$30.00
$35.00
INTERVENTION DASHBOARD DOLLARS SAVED PER CMAA BY REGION
$5.00
$10.00
$15.00
$20.00
$0.00
Q1/
2011
Q2/
2011
Q1/
2011
Q2/
2011
Q1/
2011
Q2/
2011
Q1/
2011
Q2/
2011
AK CA OR WA/MT
47
Other Results: Patient Outcomes
Readmission Rate (Pilot vs. Control)
CHF 20% l– CHF: 20% lower
– AMI: 20% lower
– AMI/CHF on Warfarin: 35% lower
Length of Stay (Pilot vs. Control)
– Overall: 1.45 day difference in mean LOSOverall: 1.45 day difference in mean LOS
• Statistically significant (p=0.001)
– ICU: 1.27 day difference in mean LOS
30 Day Readmission Rate: AMI/CHF Patients on Warfarin
‐‐‐‐: Never implemented
‐‐‐‐: Fully implemented
___: Not yet implemented
N=3,940
48
Outcomes: Significant Difference in Length of Stay
Implementation : Pilot Control
n=643,832
Clinical Pharmacy Metrics
Monitor pharmacist impact on patient careQ t l i f th b f d t d– Quarterly review of the number of documented pharmacist interventions
• High Impact: pilot results 15‐20/100 CMAA
• Total Intervention Count: 30‐35/100 CMAA
– Cost avoidance per acuity adjusted admit• Pilot group: $75 ‐ $133 per CMAAg p p
– Annual review of patient outcomes• 30 day readmission rate for AMI/CHF patients on warfarin: pilot results 15%
49
Lessons Learned
ROI can be developed in support of clinical h ti d lpharmacy practice model
Measurements of clinical and financial impact must be utilized to ensure ongoing support for staffing
Must move from “would like to do” beyondMust move from would like to do beyond “should do” and get to “need to do” status, e.g. regulatory requirement
PRACTICE MODEL TRANSFORMATIONS:Achieving excellence through accountability and innovation
Breakout Small Group Discussions # 2
‐ Approx. 20 minutes
‐ Share examples of dashboards
‐ Identify common key elements
‐ Lessons learned
‐ Prepare summary to present
50
Sixteenth Annual ASHP Conference
for Leaders in Health-System Pharmacy REFERENCES
2008 ASHP Pharmacy Staffing Survey Results.
A Perez, F Doloresco, JM Ho0ffman et al. Economic Evaluations of Clinical Pharmacy Services: 2001-2005 Pharmacotherapy 2008;28(11):285e–323e.
CA Bond, CL Raehl,. Clinical Pharmacy Services, Pharmacy Staffing, and Hospital Mortality Rates. Pharmacotherapy Vol. 27, No 4, 2007.
CA Pedersen, PJ Schneider, DJ Scheckelhoff. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing – 2010 Am J Health-Syst Pharm. 2011;68.
MA Chisholm-Burns, JS Graff Zivin, JK Lee et. al. Economic effects of pharmacists on health outcomes in the United States: A systematic review. Am J Health-Syst Pharm. 2010;67:1624-34.
SG Pickette, L Muncey, D Wham Implementation of a standard pharmacy clinical practice model in a multihospital system Am J Health-Syst Pharm. 2010;67:751-6.
SS Rough, M McDaniel, JR Rinehart Effective use of workload and productivity monitoring tools in health-system pharmacy, part 1 Am J Health-Syst Pharm. 2010;67:300-11.
Woods, Mark T; Practice Model Challenge. Am J Health-Syst Pharm. 2009;66.
53